SCHEMBL733017

SCHEMBL733017

CCOc1cc(C(=O)OC(C)(C)C)cc(OCC)c1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
HSD17B10 Q99714 2/20 0.41
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.38
CYP3A4 P08684 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
USP2 O75604 1/20 0.37
RAB9A P51151 1/20 0.37
GAA P10253 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664618 0.86 ESR1 (0.46) TSHRMEN1KMT2AGAAKDM4E
SCHEMBL9197504 0.81 MTNR1A (0.46) TSHRLMNAMEN1KMT2AHTT
SCHEMBL289285 0.81 CA12 (0.55) TSHRNCOA1NCOA3HSD17B10LMNA
SCHEMBL731013 0.81 LMNA (0.50) TSHRNCOA1NCOA3HSD17B10LMNA
SCHEMBL731961 0.81 TSHR (0.41) TSHRNCOA1NCOA3HSD17B10LMNA
SCHEMBL644658 0.80 SMPD1 (0.48) LMNAMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL10401303 0.78 TSHR (0.44) TSHRHSD17B10LMNAMAPK1SMN1; SMN2
SCHEMBL731485 0.78 TSHR (0.57) TSHRNCOA1NCOA3HSD17B10LMNA
SCHEMBL10111303 0.78 CREBBP (0.53) TSHRNCOA1NCOA3HSD17B10LMNA
SCHEMBL732996 0.77 TSHR (0.50) TSHRNCOA1NCOA3LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524730-B2 Spirochromanone carboxylic acids MSD K.K. (JP) 2013-09-03 US disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-20110077262-A1 NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS MSD K.K. (JP) 2011-03-31 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 TSHR 680/4885NCOA1 351/4885NCOA3 196/4885
US-20110077262-A1 NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS CNKSR1, CBR1, CBR3 TSHR 932/4885NCOA1 334/4885NCOA3 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.